Trevi Therapeutics (TRVI) Stock Forecast & Price Target

Compare

588 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TRVI Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Trevi

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TRVI Stock 12 Month Forecast

Average Price Target

$21.75

▲(61.47% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Trevi Therapeutics in the last 3 months. The average price target is $21.75 with a high forecast of $25.00 and a low forecast of $19.00. The average price target represents a 61.47% change from the last price of $13.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","8":"$8","14":"$14","20":"$20","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8,14,20,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.57,13.526153846153846,14.482307692307693,15.438461538461539,16.394615384615385,17.35076923076923,18.306923076923077,19.263076923076923,20.21923076923077,21.175384615384615,22.13153846153846,23.087692307692308,24.043846153846154,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.57,13.276153846153846,13.982307692307693,14.688461538461539,15.394615384615385,16.10076923076923,16.806923076923077,17.513076923076923,18.21923076923077,18.925384615384615,19.63153846153846,20.337692307692308,21.043846153846154,{"y":21.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.57,13.064615384615385,13.55923076923077,14.053846153846154,14.548461538461538,15.043076923076923,15.537692307692307,16.032307692307693,16.526923076923076,17.021538461538462,17.516153846153845,18.01076923076923,18.505384615384614,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.27,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.57,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$21.75

Lowest Price Target$19.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Debanjana Chatterjee

JonesTrading

$25

Buy

85.60%

Upside

Reiterated

03/10/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Annabel Samimy

Stifel Nicolaus

―

Buy

―

Reiterated

03/09/26

Trevi completes EOP2 with FDA, on track for Q2 Phase 3 initiation, says StifelTrevi completes EOP2 with FDA, on track for Q2 Phase 3 initiation, says Stifel

Serge Belanger

Needham

$22

Buy

63.33%

Upside

Reiterated

03/09/26

De-Risked Phase 3 Strategy and FDA Alignment Underpin Buy Rating on Trevi for Haduvio in IPF Cough

Judah Frommer

Morgan Stanley

$19

Buy

41.05%

Upside

Reiterated

03/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Brandon Folkes

H.C. Wainwright

$21

Buy

55.90%

Upside

Reiterated

03/09/26

Advancing Haduvio in IPF-Related Chronic Cough: FDA-Endorsed Phase 3 Path and Strong Cash Position Underscore Undervalued Multibillion-Dollar Opportunity for Trevi

Roanna Ruiz

Leerink Partners

$13→$16

Buy

18.78%

Upside

Reiterated

11/18/25

Trevi Therapeutics price target raised to $16 from $13 at LeerinkTrevi Therapeutics price target raised to $16 from $13 at Leerink

Joshua Schimmer

Cantor Fitzgerald

$25

Buy

85.60%

Upside

Reiterated

11/14/25

Trevi Therapeutics (TRVI) Gets a Buy from Cantor Fitzgerald

Leland Gershell

Oppenheimer

$23→$24

Buy

78.17%

Upside

Reiterated

11/14/25

Trevi Therapeutics (TRVI) Gets a Buy from Oppenheimer

Kaveri Pohlman

Clear Street

$11→$21

Buy

55.90%

Upside

Reiterated

11/14/25

Trevi Therapeutics (TRVI) Receives a Buy from Clear Street

Mayank Mamtani

B. Riley Securities

$20→$16

Buy

18.78%

Upside

Reiterated

08/14/25

B.Riley Financial Sticks to Their Buy Rating for Trevi Therapeutics (TRVI)

Ryan Deschner

Raymond James

$29→$27

Buy

100.45%

Upside

Reiterated

08/08/25

Trevi Therapeutics price target lowered to $27 from $29 at Raymond JamesTrevi Therapeutics price target lowered to $27 from $29 at Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Debanjana Chatterjee

JonesTrading

$25

Buy

85.60%

Upside

Reiterated

03/10/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Annabel Samimy

Stifel Nicolaus

―

Buy

―

Reiterated

03/09/26

Trevi completes EOP2 with FDA, on track for Q2 Phase 3 initiation, says StifelTrevi completes EOP2 with FDA, on track for Q2 Phase 3 initiation, says Stifel

Serge Belanger

Needham

$22

Buy

63.33%

Upside

Reiterated

03/09/26

De-Risked Phase 3 Strategy and FDA Alignment Underpin Buy Rating on Trevi for Haduvio in IPF Cough

Judah Frommer

Morgan Stanley

$19

Buy

41.05%

Upside

Reiterated

03/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Brandon Folkes

H.C. Wainwright

$21

Buy

55.90%

Upside

Reiterated

03/09/26

Advancing Haduvio in IPF-Related Chronic Cough: FDA-Endorsed Phase 3 Path and Strong Cash Position Underscore Undervalued Multibillion-Dollar Opportunity for Trevi

Roanna Ruiz

Leerink Partners

$13→$16

Buy

18.78%

Upside

Reiterated

11/18/25

Trevi Therapeutics price target raised to $16 from $13 at LeerinkTrevi Therapeutics price target raised to $16 from $13 at Leerink

Joshua Schimmer

Cantor Fitzgerald

$25

Buy

85.60%

Upside

Reiterated

11/14/25

Trevi Therapeutics (TRVI) Gets a Buy from Cantor Fitzgerald

Leland Gershell

Oppenheimer

$23→$24

Buy

78.17%

Upside

Reiterated

11/14/25

Trevi Therapeutics (TRVI) Gets a Buy from Oppenheimer

Kaveri Pohlman

Clear Street

$11→$21

Buy

55.90%

Upside

Reiterated

11/14/25

Trevi Therapeutics (TRVI) Receives a Buy from Clear Street

Mayank Mamtani

B. Riley Securities

$20→$16

Buy

18.78%

Upside

Reiterated

08/14/25

B.Riley Financial Sticks to Their Buy Rating for Trevi Therapeutics (TRVI)

Ryan Deschner

Raymond James

$29→$27

Buy

100.45%

Upside

Reiterated

08/08/25

Trevi Therapeutics price target lowered to $27 from $29 at Raymond JamesTrevi Therapeutics price target lowered to $27 from $29 at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Trevi Therapeutics

3 Months

xxx

Success Rate

10/12 ratings generated profit

Average Return

+28.72%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +28.72% per trade.

1 Year

Mayank MamtaniB. Riley Securities

Success Rate

17/18 ratings generated profit

Average Return

+131.29%

reiterated a buy rating 7 months ago

Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +131.29% per trade.

2 Years

xxx

Success Rate

18/18 ratings generated profit

Average Return

+234.72%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +234.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TRVI Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TRVI has received 8 Buy Ratings, 19 Hold Ratings, and 0 Sell Ratings. TRVI average Analyst price target in the past 3 months is 21.75.

Each month's total comprises the sum of three months' worth of ratings.

TRVI Financial Forecast

TRVI Earnings Forecast

Currently, no earnings data available.

No data currently available

TRVI Sales Forecast

Currently, no sales data available.

TRVI Stock Forecast FAQ

What is TRVI’s average 12-month price target, according to analysts?

Based on analyst ratings, Trevi Therapeutics Inc’s 12-month average price target is 21.75.

What is TRVI’s upside potential, based on the analysts’ average price target?

Trevi Therapeutics Inc has 61.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TRVI a Buy, Sell or Hold?

Trevi Therapeutics Inc has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Trevi Therapeutics Inc’s price target?

The average price target for Trevi Therapeutics Inc is 21.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $19.00. The average price target represents 61.47% Increase from the current price of $13.47.

What do analysts say about Trevi Therapeutics Inc?

Trevi Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of TRVI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Trevi Therapeutics (TRVI) Stock Forecast & Price Target

TRVI Analyst Ratings

TRVI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Trevi Therapeutics

TRVI Analyst Recommendation Trends

TRVI Financial Forecast

TRVI Earnings Forecast

TRVI Sales Forecast

TRVI Stock Forecast FAQ

Detailed List of Analyst Forecasts